Lacerta Therapeutics scientific board consists of scientists with deep scientific and clinical expertise in AAV gene therapy related to our proprietary technologies and clinical programs.
Todd Golde, MD, PhD
Dr. Golde is a Professor of Neuroscience and the Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida where he directs a robust program of scientific discovery aimed at translating basic discoveries in neurodegenerative disease into diagnostics and treatments for patients with Alzheimer's and Parkinson's disease.
Coy Heldermon, MD, PhD
Dr. Heldermon is an Associate Professor of Medicine at the University of Florida. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He has extensive preclinical data for the use of AAV to treat Sanfilippo syndrome B.
Ron Mandel, PhD
Dr. Mandel is a Professor of Neurosciences at the University of Florida with over 25 years experience in the study of neurodegenerative diseases, with a particular focus on Parkinson's disease. His laboratory is a leader in preclinical studies in the use of AAV for gene therapy. Prior to accepting the academic appointment in the Powell Gene Therapy Center he developed gene therapy applications for the brain in Somatix Inc. and CellGenesys Inc.
Sergei Zolotukhin, PhD
Dr. Zolotukhin is an Associate Professor of Pediatrics at the University of Florida with 30 years of experience in the gene therapy field. He has developed many of the methods for purification and quality control of AAV vectors and has pioneered the development of improved capsid engineering methods and baculovirus vector production platforms.
Arun Srivastava, PhD
Dr. Srivastava is a Professor of Pediatrics and Chief of the Division of Cellular and Molecular Therapy at the University of Florida with over 30 years of experience with AAV vectors and was the first to completely sequence AAV DNA. He has made many basic contributions to AAV biology. Most recently, he has developed over 250 different AAV capsid mutants using rational design approaches that increase transduction by up to two orders of magnitude in animal models.